Significant Ownership of Monopar Therapeutics
- Signature - Title
- Karl Leo - Managing Member
- Location
- Wilmette, IL
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Monopar Therapeutics.
Follow Filing Activity
Follow Monopar Therapeutics and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of Monopar Therapeutics
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| MNPR | Gem Pharmaceuticals LLC | Common Stock, $0.001 par value | 13% | $31,414,229 | 704,829 | Hendricks Diane | 09 Dec 2024 |
Schedules 13D/G Reported by Monopar Therapeutics:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.